{"id":398245,"date":"2020-09-24T00:00:00","date_gmt":"2020-09-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoop0002-2020-biopharma-glaucoma-special-topics-us-2020\/"},"modified":"2026-03-31T10:44:31","modified_gmt":"2026-03-31T10:44:31","slug":"sptoop0002-2020-biopharma-glaucoma-special-topics-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoop0002-2020-biopharma-glaucoma-special-topics-us-2020\/","title":{"rendered":"Glaucoma | Special Topics | US | 2020"},"content":{"rendered":"<p>The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years with the launch of novel topical drugs (e.g., Aerie Pharmaceuticals\u2019 Rhopressa and Rocklatan, Bausch + Lomb\u2019s Vyzulta). Although topical eye drops are the central pillar of OAG treatment, innovative approaches such as sustained-release formulations of some key OAG drugs (e.g., AbbVie\u2019s Durysta) and developments in the field of devices for minimally invasive glaucoma surgery (MIGS) offer promising nontopical treatment options for ophthalmologists and glaucoma specialists treating OAG patients.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What factors most influence physicians\u2019 choice of a drug in the prostaglandin analogue and fixed-dose combination drug classes in OAG?<\/li>\n<li>What are the key drivers and constraints for physicians in prescribing the newer-to-market drugs Rhopressa, Rocklatan,\u00a0Vyzulta, and Xelpros in OAG?<\/li>\n<li>What has been\u00a0the impact of COVID-19 on physician prescribing in OAG?<\/li>\n<li>How will sustained-release implants (i.e.,\u00a0Durysta, Glaukos&#8217;s\u00a0iDose TR) and novel topical drugs (i.e.,\u00a0Santen&#8217;s DE-117 and Nicox&#8217;s NCX 470)\u00a0fit into physicians&#8217; treatment practice for OAG? What\u00a0factors would\u00a0persuade physicians to prescribe\u00a0these drugs more in OAG?<\/li>\n<li>How will the use of surgical approaches (i.e., selective laser trabeculoplasty in treatment-naive patients and\u00a0MIGS) evolve in OAG in the near future?\u00a0What is the physicians&#8217;\u00a0likelihood of using Santen \/ Glaukos\u2019s Preserflo MicroShunt (DE-128) in OAG?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geography: <\/strong>United States.<\/p>\n<p><strong>Primary Research:<\/strong> Survey of 102 U.S. ophthalmologists \/ glaucoma specialists.\u00a0<\/p>\n<p><strong>Key Drugs Covered:\u00a0<\/strong>Rhopressa, Rocklatan, Vyzulta, Xelpros, Durysta, iDose TR, DE-117, NCX 470, Lumigan, Travatan Z, Xalatan, Cosopt PF, Combigan, Simbrinza,\u00a0 Alphagan P, latanoprost.<\/p>\n<p><strong>Key Insights\u00a0Provided:<\/strong><\/p>\n<ul>\n<li>Physician-reported treatment practices and patient shares in OAG.<\/li>\n<li>Factors influencing treatment decisions in OAG.<\/li>\n<li>Drivers and constraints of treatment selection in OAG.<\/li>\n<li>Familiarity with and\/or impressions of newer-to-market and key emerging therapies for OAG.<\/li>\n<li>Expected use patterns of key emerging therapies for OAG.<\/li>\n<\/ul>\n<p><strong lang=\"en-US\">PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em lang=\"en-US\">Special Topics <\/em>assesses key trends in dynamic disease areas. This report on glaucoma will help drug marketers and developers gain insight into the current and anticipated impact of newer-to-market and key emerging therapies and approaches on physician prescribing decisions for the treatment of glaucoma in the United States.<\/p>\n","protected":false},"template":"","class_list":["post-398245","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-glaucoma","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/398245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/398245\/revisions"}],"predecessor-version":[{"id":398582,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/398245\/revisions\/398582"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=398245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}